Stock Movers BP Spin Off, Abivax's 1600% Gains, B&M's Woes
Dec 24, 2025
Kit Reese, a seasoned market analyst, joins to unravel the intriguing movements in recent stock trends. He dives into BP's $6 billion sale of a majority stake in its Castrol division, explaining the company's strategic pivot back to oil and gas amidst activist pressure. Reese also highlights the astonishing 1,600% rally of French biotech firm Abivax, buoyed by promising trial results for its ulcerative colitis drug. On the flip side, he examines B&M's staggering 56% stock decline, influenced by rising competition and operational hurdles.
AI Snips
Chapters
Transcript
Episode notes
BP Cuts Noncore Assets To Refocus
- BP is selling a 65% stake in Castrol to Stonepeak to raise about $6 billion.
- The move signals BP's pivot back to oil and gas and a focus on core fossil-fuel assets under activist pressure.
Biotech Rocket Fueled By Trial Wins
- Abivax surged over 1,600% after positive trial results for a bowel disease drug.
- The company faces key phase III and Crohn's trial results next year that will determine if gains are sustainable.
Monitor Upcoming Trial Catalysts
- Watch Abivax's phase III maintenance results in Q2 and Crohn's data in H2 before assuming the rally continues.
- Treat current gains as contingent on upcoming trial catalysts rather than permanent valuation gains.